Human Genome Sciences Inc's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Human Genome Sciences Inc in the second quarter 2012?
Human Genome Sciences Inc recorded a cumulative net loss of $-356 million during 12 months ending in the second quarter 2012, resulting in a negative return on equity (ROE) of -89.92%.

Within the Medical Laboratories industry 6 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2012 from to 2202.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2012) II. Quarter	(Mar 31 2012) I. Quarter	(Dec 31 2011) IV. Quarter	(Sep 30 2011) III. Quarter	(Jun 30 2011) II. Quarter
Y / Y Equity Change	-25.85 %	-19.03 %	-22.08 %	-	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-356	-344	-381	-388	-340
Return On Equity (TTM)	-89.92 %	-81.46 %	-85.84 %	-81.4 %	-93.42 %
HGSI's Total Ranking	# 2202	#	#	#	#
Equity (TTM) in Millions	301	377	456	449	405
Seq. Equity Change	-20.18 %	-17.47 %	1.7 %	10.69 %	-12.85 %
Seq. Net Income Change	-	-	-	-	-

Back to HGSI Management Effectiveness >> HGSI's 5 Years Annual ROE >> Compare HGSI ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 7
Sector	# 160
Overall	# 2202

Return On Equity Statistics
High	Average	Low
-81.46 %	-85.74 %	-89.92 %
(Mar 31 2012)		(Jun 30 2012)

HGSI Annual Return On Equity	(Dec 31 2009) 2011
Total Equity in Millions	586	0	0	0	0
Y / Y Equity Change	-	-	-	-	-
Net Income in Millions	6	0	0	0	0
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	0.97 %	-	-	-	-

Back to HGSI Management Effectiveness >> HGSI's 5 Years Annual ROE >> Compare HGSI ROE to its Competitors

Annual Roe Comment

In 2011 ROE improved to 0.97 % compared to the previous year, due to net income growth.

More Return On Equity Ratios
Medical Laboratories Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
HGSI's' Return on Equity at Yahoo Finance
HGSI's Roe Ratio versus Medical Laboratories Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for HGSI's Competitors
Subscribers only: Roe for Human Genome Sciences Inc's Suppliers
Subscribers only: Return On Equity for HGSI's Customers

Companies with similar Return On Equity at Jun 30 2012, within Healthcare Sector

ROE

Date modified: 2026-09-08T15:07:12+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.